Global Liposome Finished Pharmaceuticals Market Research Report 2025

Publication ID:

PB505251217

Publication Date:

May 22, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Liposome Finished Pharmaceuticals was valued at US$ 6064 million in the year 2024 and is projected to reach a revised size of US$ 11710 million by 2031, growing at a CAGR of 10.0% during the forecast period.
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market"s potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
This report aims to provide a comprehensive presentation of the global market for Liposome Finished Pharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Finished Pharmaceuticals.
The Liposome Finished Pharmaceuticals market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Liposome Finished Pharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposome Finished Pharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposome Finished Pharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposome Finished Pharmaceuticals Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
1.3 Market by Application
1.3.1 Global Liposome Finished Pharmaceuticals Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposome Finished Pharmaceuticals Market Perspective (2020-2031)
2.2 Global Liposome Finished Pharmaceuticals Growth Trends by Region
2.2.1 Global Liposome Finished Pharmaceuticals Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Liposome Finished Pharmaceuticals Historic Market Size by Region (2020-2025)
2.2.3 Liposome Finished Pharmaceuticals Forecasted Market Size by Region (2026-2031)
2.3 Liposome Finished Pharmaceuticals Market Dynamics
2.3.1 Liposome Finished Pharmaceuticals Industry Trends
2.3.2 Liposome Finished Pharmaceuticals Market Drivers
2.3.3 Liposome Finished Pharmaceuticals Market Challenges
2.3.4 Liposome Finished Pharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposome Finished Pharmaceuticals Players by Revenue
3.1.1 Global Top Liposome Finished Pharmaceuticals Players by Revenue (2020-2025)
3.1.2 Global Liposome Finished Pharmaceuticals Revenue Market Share by Players (2020-2025)
3.2 Global Liposome Finished Pharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Liposome Finished Pharmaceuticals Revenue
3.4 Global Liposome Finished Pharmaceuticals Market Concentration Ratio
3.4.1 Global Liposome Finished Pharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposome Finished Pharmaceuticals Revenue in 2024
3.5 Global Key Players of Liposome Finished Pharmaceuticals Head office and Area Served
3.6 Global Key Players of Liposome Finished Pharmaceuticals, Product and Application
3.7 Global Key Players of Liposome Finished Pharmaceuticals, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposome Finished Pharmaceuticals Breakdown Data by Type
4.1 Global Liposome Finished Pharmaceuticals Historic Market Size by Type (2020-2025)
4.2 Global Liposome Finished Pharmaceuticals Forecasted Market Size by Type (2026-2031)
5 Liposome Finished Pharmaceuticals Breakdown Data by Application
5.1 Global Liposome Finished Pharmaceuticals Historic Market Size by Application (2020-2025)
5.2 Global Liposome Finished Pharmaceuticals Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Liposome Finished Pharmaceuticals Market Size (2020-2031)
6.2 North America Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Liposome Finished Pharmaceuticals Market Size by Country (2020-2025)
6.4 North America Liposome Finished Pharmaceuticals Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposome Finished Pharmaceuticals Market Size (2020-2031)
7.2 Europe Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Liposome Finished Pharmaceuticals Market Size by Country (2020-2025)
7.4 Europe Liposome Finished Pharmaceuticals Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposome Finished Pharmaceuticals Market Size (2020-2031)
8.2 Asia-Pacific Liposome Finished Pharmaceuticals Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Liposome Finished Pharmaceuticals Market Size by Region (2020-2025)
8.4 Asia-Pacific Liposome Finished Pharmaceuticals Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposome Finished Pharmaceuticals Market Size (2020-2031)
9.2 Latin America Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Liposome Finished Pharmaceuticals Market Size by Country (2020-2025)
9.4 Latin America Liposome Finished Pharmaceuticals Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposome Finished Pharmaceuticals Market Size (2020-2031)
10.2 Middle East & Africa Liposome Finished Pharmaceuticals Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Liposome Finished Pharmaceuticals Market Size by Country (2020-2025)
10.4 Middle East & Africa Liposome Finished Pharmaceuticals Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Details
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Liposome Finished Pharmaceuticals Introduction
11.1.4 Johnson & Johnson Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Details
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Liposome Finished Pharmaceuticals Introduction
11.2.4 Sun Pharmaceutical Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Details
11.3.2 CSPC Business Overview
11.3.3 CSPC Liposome Finished Pharmaceuticals Introduction
11.3.4 CSPC Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Details
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Liposome Finished Pharmaceuticals Introduction
11.4.4 Kinyond Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Details
11.5.2 Teva Business Overview
11.5.3 Teva Liposome Finished Pharmaceuticals Introduction
11.5.4 Teva Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Details
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Liposome Finished Pharmaceuticals Introduction
11.6.4 Fudan-Zhangjiang Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Details
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Liposome Finished Pharmaceuticals Introduction
11.7.4 Zydus Cadila Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Details
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Liposome Finished Pharmaceuticals Introduction
11.8.4 TTY Biopharma Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Details
11.9.2 Pacira Business Overview
11.9.3 Pacira Liposome Finished Pharmaceuticals Introduction
11.9.4 Pacira Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Details
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Liposome Finished Pharmaceuticals Introduction
11.10.4 Luye Pharma Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Details
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Liposome Finished Pharmaceuticals Introduction
11.11.4 Leadiant Biosciences Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Details
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Liposome Finished Pharmaceuticals Introduction
11.12.4 Ipsen Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Details
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Liposome Finished Pharmaceuticals Introduction
11.13.4 Sayre Therapeutics Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Details
11.14.2 Jazz Business Overview
11.14.3 Jazz Liposome Finished Pharmaceuticals Introduction
11.14.4 Jazz Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Details
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Liposome Finished Pharmaceuticals Introduction
11.15.4 Alnylam Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Details
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Liposome Finished Pharmaceuticals Introduction
11.16.4 Bausch Health Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Details
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Liposome Finished Pharmaceuticals Introduction
11.17.4 Acrotech Biopharma Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Liposome Finished Pharmaceuticals Introduction
11.18.4 Takeda Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Details
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Liposome Finished Pharmaceuticals Introduction
11.19.4 Chiesi Farmaceutici Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Details
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Liposome Finished Pharmaceuticals Introduction
11.20.4 Gilead Sciences Revenue in Liposome Finished Pharmaceuticals Business (2020-2025)
11.20.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂